Report data from the VX-548 bunionectomy acute pain trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Jul 2021
- Due
- 31 Mar 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data from the bunionectomy trial are expected by early 2022.”
What we found
Evidence strength A What the grades mean
Later filings state Vertex reported positive Phase 2 VX-548 acute pain data, including the bunionectomy study, in March 2022, within the early-2022 deadline.
-
A Vertex Pharmaceuticals 8-K filed 2022-05-05
“In March, Vertex reported positive data from two Phase 2 dose ranging acute pain studies with VX-548, one following bunionectomy surgery and the other following abdominoplasty surgery.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In March 2022, we announced positive Phase 2 data for VX-548, a NaV1.8 inhibitor, for treatment of acute pain.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In early 2022, we reported positive data from two Phase 2 acute pain clinical trials for VX-548, a NaV1.8 inhibitor.” ✓ confirmed on the page
Market reaction: the shares moved -6.9% against the S&P 500 over the three sessions around the disclosure (4 May 2022 to 9 May 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- VX-548 bunionectomy acute pain trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Low
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VRTX-006498 · Corrections policy